The drugmaker is prioritizing vaccine development against high-priority pathogens, including HIV, tuberculosis and malaria, identified by the World Health Organization and the Coalition for Epidemic Preparedness Innovations.
Moderna said its clinical portfolio currently includes vaccines targeting COVID-19, HIV, Nipah and Zika, with plans to advance programs against the remaining pathogens by 2025.
The initiative is part of Moderna’s larger global public health strategy released March 7, which also includes a new program, mRNA Access, that offers global researchers use of the drugmaker’s mRNA technology to explore new vaccines.
To learn more, click here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.